BrainChild Bio gets $116M for pivotal trial of pediatric brain tumor CAR-T

BrainChild Bio raises a $116M Series A to fund a pivotal B7-H3 CAR-T trial for pediatric brain tumor DIPG. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo…

Kyle LaHucik · 2026-09-08

A Seattle biotech trying to flip the script on CAR-T cell therapies — making them akin to small molecules for brain tumors — has put together a megaround with the hopes of becoming a commercial-stage company around ...

Source: Endpoints News